News|Videos|August 1, 2024

Emerging Treatments in Mild/Moderate Multiple Sclerosis

Key opinion leaders examine the available data on Bruton tyrosine kinase (BTK) inhibitors to assess whether the evidence supports their efficacy as a treatment option for multiple sclerosis (MS).

BTK inhibitors: Do the current data suggest this strategy for mild MS?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME